Treatment of newly diagnosed moderate or severe chronic graft-versus-host disease with prednisone and everolimus (PredEver first) - A prospective multicenter phase IIA study

Trial Profile

Treatment of newly diagnosed moderate or severe chronic graft-versus-host disease with prednisone and everolimus (PredEver first) - A prospective multicenter phase IIA study

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2018

At a glance

  • Drugs Everolimus (Primary) ; Prednisone (Primary) ; Prednisone (Primary)
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Acronyms PredEver first
  • Most Recent Events

    • 18 Apr 2018 Planned End Date changed from 31 Jan 2018 to 1 Jun 2018.
    • 04 Apr 2018 This trial has been completed in Germany, according to European Clinical Trials Database (on-2018-02-07) record.
    • 07 May 2017 Planned End Date changed from 1 Jul 2017 to 31 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top